<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02677584</url>
  </required_header>
  <id_info>
    <org_study_id>R / 15.06.75</org_study_id>
    <nct_id>NCT02677584</nct_id>
  </id_info>
  <brief_title>Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity</brief_title>
  <official_title>Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University Children Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesized that the timing of caffeine administration in either prophylaxis
      or treatment of apnea of prematurity will affect the apnea response to caffeine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It will be a randomized control trial, patients will be randomly assigned to receive caffeine
      in a loading dose of 20 mg/kg (equivalent for 10 mg/kg caffeine base) and a maintenance dose
      of 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) either as a prophylaxis group (1) or
      therapeutic group (2) . Prophylactic caffeine (group 1) will be defined as caffeine
      prescribed for preterm infant within the first 72 hours of life prior to manifest apnea ,
      therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea
      within or after the first 72 hours of life .

      Preparation and administration of caffeine will be performed by a Neonatal intensive care
      unit (NICU) nurse.

      Statistical Evaluation:

      Statistical analyses will be performed with the Statistical Package for Social Sciences-SPSS
      version 16 software (SPSS Inc, Chicago, Illinois). For categorical variables, the X2 test
      will be used. For group comparisons, the Student T test will be used in normal distribution
      and the Mann-Whitney U test will be used in case of abnormal distribution.

      For repeating measurements, variance analyses and Friedman variance analyses will be used.
      For descriptive statistics, percent, minimum-maximum-median, mean, and standard deviation
      will be used in accordance with the type and distribution of the variable. A P value &lt;.05 was
      considered statistically significant. Informed consent will be obtained from parents, and the
      study will be approved by the local ethical committee.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Respiratory Support</measure>
    <time_frame>60 days from NICU admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days of apnea free</measure>
    <time_frame>60 days from NICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>60 days from NICU admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head ultrasound results</measure>
    <time_frame>14 days from NICU admission</time_frame>
    <description>Any grade of intraventricular hemorrhage (IVH); periventricular leukomalacia (PVL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necrotizing Enterocolitis</measure>
    <time_frame>30 days from NICU admission</time_frame>
    <description>Any stage, according to modified Bell classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinopathy of prematurity</measure>
    <time_frame>60 days from NICU admission</time_frame>
    <description>Any stage, according to International classification of retinopathy of prematurity (ICROP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Apnea</condition>
  <arm_group>
    <arm_group_label>Prophylactic caffeine citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapeutic caffeine citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prophylactic caffeine citrate</intervention_name>
    <description>Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .</description>
    <arm_group_label>Prophylactic caffeine citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Therapeutic caffeine citrate</intervention_name>
    <description>Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).</description>
    <arm_group_label>Therapeutic caffeine citrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants eligible for this study will be newborn infants â‰¤ 32 weeks with or without a
             diagnosis of apnea .

        Exclusion Criteria:

          -  Newborn infants with gestational age &gt; 32 weeks.

          -  Newborn infants with congenital malformations and chromosomal anomalies.

          -  Newborn infants with apnea of other causes .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mansoura University Children Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>El Dakahlya</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>nehad a nasef, MD</last_name>
      <phone>01001229299</phone>
      <phone_ext>002</phone_ext>
      <email>nehad_nasef@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S, Herring A, Laughon MM, Carlton D, Hunt CE. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr. 2014 May;164(5):992-998.e3. doi: 10.1016/j.jpeds.2013.12.025. Epub 2014 Jan 23. Erratum in: J Pediatr. 2014 May;164(5):1244.</citation>
    <PMID>24461786</PMID>
  </reference>
  <reference>
    <citation>Katheria AC, Sauberan JB, Akotia D, Rich W, Durham J, Finer NN. A Pilot Randomized Controlled Trial of Early versus Routine Caffeine in Extremely Premature Infants. Am J Perinatol. 2015 Jul;32(9):879-86. doi: 10.1055/s-0034-1543981. Epub 2015 Jan 21.</citation>
    <PMID>25607226</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University Children Hospital</investigator_affiliation>
    <investigator_full_name>Nehad Nasef</investigator_full_name>
    <investigator_title>Principle Invistigator</investigator_title>
  </responsible_party>
  <keyword>caffeine</keyword>
  <keyword>apnea</keyword>
  <keyword>preterm infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Caffeine citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

